VERRICA PHARMACEUTICALS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.67 USD | -5.25% |
|
+8.38% | +18.44% |
Presenter SpeechTed White (Executives)Good afternoon, everyone. So I'll give you a little bit ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Verrica Pharmaceuticals Inc. is a dermatology therapeutics company. The Company is focused on developing and commercializing treatments for skin diseases. Its product pipeline consists of three product candidates: YCANTH, VP-315 and VP-103. YCANTH is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. We are also developing YCANTH for potential follow-on indications for the treatment of common warts and external genital warts. In addition, the Company is also developing YCANTH for the treatment of external genital warts, or external genital warts EGW. Its second candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma, non-metastatic melanoma, and non-metastatic Merkel cell carcinoma. VP-103, a second cantharidin based drug device combination for the potential treatment of plantar warts.
Sector
Pharmaceuticals
Calendar
2024-06-06
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
D
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
8.67
USD
Average target price
14.17
USD
Spread / Average Target
+63.40%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +18.44% | 368M | |
| +32.09% | 693B | |
| +29.39% | 584B | |
| -1.34% | 372B | |
| +20.34% | 332B | |
| +7.39% | 294B | |
| +14.25% | 239B | |
| -3.03% | 211B | |
| +10.02% | 210B | |
| +8.49% | 168B |
- Stock Market
- Equities
- VRCA Stock
- News Verrica Pharmaceuticals Inc.
- Transcript : Verrica Pharmaceuticals Inc. Presents at Bank of America Merrill Lynch 2019 Healthcare Conference, May-14-2019 02
